Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience
OPEN medRxiv : the preprint server for health sciences | 21 Aug 2020
MJ Joyner, JW Senefeld, SA Klassen, JR Mills, PW Johnson, ES Theel, CC Wiggins, KA Bruno, AM Klompas, ER Lesser, KL Kunze, MA Sexton, JC Diaz Soto, SE Baker, JRA Shepherd, N van Helmond, CM van Buskirk, JL Winters, JR Stubbs, RF Rea, DO Hodge, V Herasevich, ER Whelan, AJ Clayburn, KF Larson, JG Ripoll, KJ Andersen, MR Buras, MNP Vogt, JJ Dennis, RJ Regimbal, PR Bauer, JE Blair, NS Paneth, D Fairweather, RS Wright, RE Carter and A Casadevall
Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease 2019 (COVID-19), but the efficacy remains uncertain.
* Data courtesy of Altmetric.com